hengrui glp-1 Investors put $400M into biotech licensing obesity drugs from China Hengrui's GLP-1/GIP agonist posts 18%

adults was conducted in November 2025 to understand perceptions and experiences surrounding GLP-1 access and affordability

For individuals who don't have insurance coverage and can't afford brand-name medications, compounded options through telehealth platforms may make GLP-1 treatment financially feasible

FDAs Concerns With Unapproved GLP-1 Drugs Used for Weight Loss

Turns out tirzepatide could be a frontrunner in the medication category because of its ability to target weight, help blood sugar regulation, and potentially reduce other PCOS symptoms

Obagi: benefits continue as long as you use the products consistently

Others find themselves spiraling into emotional eating